Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
87,37 CHF | +0,82 % | +0,75 % | +2,95 % |
13:29 | NOVARTIS AG : Barclays mantiene una recomendación de venta | ZD |
25/03 | NOVARTIS AG : Berenberg permanece neutral | ZD |
Resumen de negocios
- oncología (29,9%);
- inmunología (17,2%)
- enfermedades cardiovasculares, renales y metabólicas (14,1%)
- neurociencia (8,9%).
El resto de las ventas netas (29,9%) procede de la fabricación por contrato de productos farmacéuticos.
A finales de 2023, Novartis AG contaba con 33 centros de producción en todo el mundo.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Europa (33%), Estados Unidos (39,5%), Asia/África/Australasia (20,5%), Canadá y Latinoamérica (7%).
Número de empleados: 76 057
Ventas por actividad
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Established Brands
30,0
%
| - | - | 12 238 | 30,0 % | - |
Oncology
29,9
%
| - | - | 12 213 | 29,9 % | - |
Immunology
17,2
%
| - | - | 7 008 | 17,2 % | - |
Cardiovascular, Renal and Metabolic
14,1
%
| - | - | 5 743 | 14,1 % | - |
Neuroscience
8,9
%
| - | - | 3 633 | 8,9 % | - |
Ventas por región
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
39,5
%
| 16 860 | 34,9 % | 16 139 | 39,5 % | -4,28 % |
Europe
18,9
%
| 10 469 | 21,7 % | 7 704 | 18,9 % | -26,41 % |
Asia/Africa/Australasia
9,1
%
| 4 975 | 10,3 % | 3 700 | 9,1 % | -25,63 % |
Germany
7,4
%
| 4 086 | 8,5 % | 3 026 | 7,4 % | -25,94 % |
China
7,2
%
| 2 987 | 6,2 % | 2 936 | 7,2 % | -1,73 % |
Canada and Latin America
7,0
%
| 3 709 | 7,7 % | 2 854 | 7,0 % | -23,04 % |
Japan
4,2
%
| 2 106 | 4,4 % | 1 729 | 4,2 % | -17,90 % |
France
3,8
%
| 2 156 | 4,5 % | 1 572 | 3,8 % | -27,09 % |
Switzerland
2,9
%
| 926 | 1,9 % | 1 175 | 2,9 % | +26,88 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 48 | 01/01/05 | |
Director of Finance/CFO | 59 | 01/01/03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16/05/22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 01/04/17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 01/12/18 |
Samir Shah
IRO | Public Communications Contact | 63 | 01/01/04 |
Simon Brown
PRN | Corporate Officer/Principal | - | 01/08/13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 01/05/22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 01/09/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01/01/13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28/02/20 |
Chairman | 68 | 01/01/13 | |
John Young
BRD | Director/Board Member | 60 | 07/03/23 |
Bridgette Heller
BRD | Director/Board Member | 63 | 28/02/20 |
Ton Büchner
BRD | Director/Board Member | 59 | 01/01/16 |
Charles Sawyers
BRD | Director/Board Member | 65 | 01/01/13 |
Nancy Andrews
BRD | Director/Board Member | 66 | 01/01/15 |
Patrice Bula
BRD | Director/Board Member | 68 | 28/02/19 |
Frans van Houten
BRD | Director/Board Member | 63 | 28/02/17 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 2 277 477 752 | 1 866 336 959 ( 81,95 %) | 233 443 766 ( 10,25 %) | 81,95 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
NOVARTIS AG 6.37% | 145 083 991 | 6.37% | 14 744 836 677 $ |
SANDOZ GROUP AG 4.30% | 18 524 209 | 4.30% | 577 678 384 $ |
NOVARTIS INDIA LIMITED 70.68% | 17 450 680 | 70.68% | 198 486 303 $ |
ERASCA, INC. 8.15% | 12 307 692 | 8.15% | 29 292 307 $ |
THIRD HARMONIC BIO, INC. 6.55% | 2 642 762 | 6.55% | 26 797 607 $ |
5 908 089 | 6.18% | 23 396 032 $ | |
OCULIS HOLDING AG 4.68% | 1 713 521 | 4.68% | 20 390 900 $ |
MOLECULAR PARTNERS AG 4.78% | 1 739 130 | 4.78% | 7 712 572 $ |
413 577 | 6.51% | 7 651 175 $ | |
GAMIDA CELL LTD. 3.27% | 4 336 759 | 3.27% | 1 561 233 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis BioVenturesAG
Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The private company is based in Basel, Switzerland. |
Investment Managers
|
Pharmaceuticals: Major
| |
Novartis Securities Investment Ltd.
Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The private company is located in Bermuda. |
Investment Managers
|
EBEWE Pharma Ges.m.b.H. Nfg.KG
EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria. |
Pharmaceuticals: Major
|
Novartis Capital Corp.
Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ. |
Finance/Rental/Leasing
|
Novartis Finance SA
|
Finance/Rental/Leasing
|
Sandoz GmbH
Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. |
Pharmaceuticals: Major
|
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+2,95 % | 210 mil M | |
+35,06 % | 701 mil M | |
+26,24 % | 571 mil M | |
+0,89 % | 381 mil M | |
+20,84 % | 334 mil M | |
+16,82 % | 319 mil M | |
+0,74 % | 210 mil M | |
-6,05 % | 201 mil M | |
-3,18 % | 157 mil M | |
-0,83 % | 153 mil M |
- Bolsa
- Acciones
- Acción Novartis AG - Swiss Exchange
- Empresa Novartis AG